C4 Therapeutics (CCCC) PT Lowered to $18 at UBS, 'well funded, multiple catalysts - one to watch in '24'
Tweet Send to a Friend
UBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $18.00 (from $19.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
